Výsledky vyhledávání - "Hiroki Yagura"

Akademický článek

Association between tenofovir plasma trough concentrations in the early stage of administration and discontinuation of up to five years tenofovir disoproxil fumarate due to renal function-related adverse events in Japanese HIV-1 infected patients

Autor: Hiroki Yagura, Dai Watanabe, Takao Nakauchi, Hiroyuki Kushida, Kazuyuki Hirota, Yasuharu Nishida, Munehiro Yoshino, Tomoko Uehira, Takuma Shirasaka

Publikováno v: Journal of Pharmaceutical Health Care and Sciences, Vol 10, Iss 1, Pp 1-7 (2024)

Abstract Background The relationship between plasma tenofovir (TFV) concentration at the beginning of tenofovir disoproxil fumarate (TDF) administration and the development of renal dysfunction during long-term administration of TDF has not been demo

Externí odkaz: https://doaj.org/article/68764e78eae34d859cec735488606237

Zobrazit plný text záznamu

Akademický článek

Adherence to anti-retroviral therapy, decisional conflicts, and health-related quality of life among treatment-naïve individuals living with HIV: a DEARS-J observational study

Autor: Yusuke Sekine, Takashi Kawaguchi, Yusuke Kunimoto, Junichi Masuda, Ayako Numata, Atsushi Hirano, Hiroki Yagura, Masashi Ishihara, Shinichi Hikasa, Mariko Tsukiji, Tempei Miyaji, Takuhiro Yamaguchi, Ei Kinai, Kagehiro Amano

Publikováno v: Journal of Pharmaceutical Health Care and Sciences, Vol 9, Iss 1, Pp 1-11 (2023)

Abstract Background Supporting people living with HIV using anti-retroviral therapy (ART) is important due to the requirement for strict medication adherence. To date, no data from longitudinal studies evaluating adherence by treatment-naïve people

Externí odkaz: https://doaj.org/article/73dae0918a5043aa97c4394c610203fe

Zobrazit plný text záznamu

Akademický článek

Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1

Autor: Hiroki Yagura, Dai Watanabe, Hiroyuki Kushida, Kosuke Tomishima, Hiroaki Togami, Atsushi Hirano, Masaaki Takahashi, Kazuyuki Hirota, Motoko Ikuma, Daisuke Kasai, Yasuharu Nishida, Munehiro Yoshino, Kunio Yamazaki, Tomoko Uehira, Takuma Shirasaka

Publikováno v: BMC Infectious Diseases, Vol 17, Iss 1, Pp 1-8 (2017)

Abstract Background Dolutegravir (DTG) is metabolized mainly by uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1), and partly by cytochrome P450 3A (CYP3A). Therefore, we focused on UGT1A1 gene polymorphisms (*6 and *28) in Japanese indi

Externí odkaz: https://doaj.org/article/e4cf4872594949048e92b79b10b7e62c

Zobrazit plný text záznamu

Effects of Milk or Apple Juice Ingestion on the Pharmacokinetics of Elvitegravir and Cobicistat in Healthy Japanese Male Volunteers: A Randomized, Single-Dose, Three-Way Crossover Study

Autor: Hiroki Yagura, Toshiaki Iida, Hideki Ozaki, Kazuhiro Okamiya, Takuma Yonemura, Koichi Sagane, Hiroyuki Yamada, Nozomi Okada

Publikováno v: Clinical Pharmacology in Drug Development. 7:737-743

Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (EVG/COBI/FTC/TAF) is specified in its package insert to be taken with food to obtain sufficient exposure of EVG. It has been reported that a nutritional protein-rich drink shows comparable

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfa9bad42ec0227b30d05976ea45ad44
https://doi.org/10.1002/cpdd.425

Zobrazit plný text záznamu

Plný text ve formátu HTML

Correlation between UGT1A1 polymorphisms and raltegravir plasma trough concentrations in Japanese HIV-1-infected patients

Autor: Takuma Shirasaka, Hiroki Yagura, Motoko Ikuma, Dai Watanabe, Kazuyuki Hirota, Yasuharu Nishida, Munehiro Yoshino, Yoshihiko Ogawa, Hiroyuki Kushida, Daisuke Kasai, Misa Ashida, Keishiro Yajima, Tomoko Uehira

Publikováno v: Journal of Infection and Chemotherapy. 21:713-717

Raltegravir (RAL), an HIV integrase inhibitor, is metabolized mainly by UDP-glucuronosyltransferase 1A1 (UGT1A1). Polymorphisms in UGT1A1 may cause alterations in the pharmacodynamics of RAL, which is taken twice daily with no dietary restrictions. W

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9f48962d6cfef44c4debbf30ac1d426
https://doi.org/10.1016/j.jiac.2015.06.008

Zobrazit plný text záznamu

Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1

Autor: Tomoko Uehira, Masaaki Takahashi, Hiroaki Togami, Takuma Shirasaka, Munehiro Yoshino, Kunio Yamazaki, Kazuyuki Hirota, Atsushi Hirano, Motoko Ikuma, Dai Watanabe, Kosuke Tomishima, Yasuharu Nishida, Daisuke Kasai, Hiroyuki Kushida, Hiroki Yagura

Publikováno v: BMC Infectious Diseases
BMC Infectious Diseases, Vol 17, Iss 1, Pp 1-8 (2017)

Background Dolutegravir (DTG) is metabolized mainly by uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1), and partly by cytochrome P450 3A (CYP3A). Therefore, we focused on UGT1A1 gene polymorphisms (*6 and *28) in Japanese individuals i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acfee31351aa1c70621128f0b9a1e858
https://pubmed.ncbi.nlm.nih.gov/28915895

Zobrazit plný text záznamu

Therapeutic Drug Monitoring of Anti-human Immunodeficiency Virus Drugs in a Patient with Short Bowel Syndrome

Autor: Tadafumi Asaoka, Dai Watanabe, Tomoko Uehira, Hiroki Yagura, Wataru Sugiura, Takuma Shirasaka, Motoko Ikuma, Masaaki Shibata, Misa Ashida, Munehiro Yoshino, Masaaki Takahashi

Publikováno v: Internal Medicine

An elderly woman with human immunodeficiency virus-1 infection developed short bowel syndrome as a result of extensive intestinal resection. Considering the possibility of poor absorption of antiretroviral drugs (ARVs), therapeutic drug monitoring (T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9b4580d757035261077e664ff759f7d
https://pubmed.ncbi.nlm.nih.gov/27746450

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání